COAs And DHTs And Post-Approval Monitoring

Source: Cytiva

In this segment of Cell & Gene Live, Regulating The CGT Workflow To Improve Patient Safety, Nimi Chhina, Ph.D., J.D. Executive Director, Head of Global R&D and Regulatory Policy Global Regulatory Affairs, Worldwide Research & Development at BioMarin Pharmaceutical Inc. and Robert G. Pietrusko, Pharm.D., Chief Regulatory & Quality Officer at Vor Biopharma share their thoughts on the use of clinical outcome assessment (COA) tools and digital health technologies (DHTs) to support cell and gene therapy product development.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene